Experience

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…

Davis Polk advised the representatives of the several initial purchasers in connection with the offering by Seagate HDD Cayman of $500 million aggregate principal amount of its 4.125%…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised Clarivate Plc in connection with the $1.08 billion SEC-registered offering of 48,000,000 of its ordinary shares, of which 14,000,000 ordinary shares were issued and sold…

Davis Polk advised the representatives of the initial purchasers in a Rule 144A/Regulation S offering by Macy’s, Inc. of $1.3 billion aggregate principal amount of its 8.375% senior…

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by Palo Alto Networks, Inc. of an aggregate principal amount of $2…

Davis Polk advised the representative of the several underwriters in connection with an underwritten secondary offering of 14,130,523 shares of common stock of Werner Enterprises, Inc. by…

Davis Polk advised the joint book-running managers in connection with the $212 million SEC-registered follow-on offering of 2,995,757 shares of Class A common stock of Hamilton Lane…

Davis Polk advised the initial purchasers in a Rule 144A offering by Splunk Inc. of $1.265 billion aggregate principal amount of 1.125% convertible senior notes due 2027, including $165…

Davis Polk advised the joint book-running managers on the SEC-registered offering by SVB Financial Group of $500 million aggregate principal amount of the company’s 3.125% senior notes…